Choosing a dipeptidyl peptidase-4 inhibitor in adults with type 2 diabetes and co‑morbidities

20200311 DPP-4 inhibitor GinP supplement v10 digital version draft

This supplement has been commissioned and funded by Boehringer Ingelheim Limited and developed in partnership with Guidelines in Practice. Boehringer Ingelheim Limited suggested the topic and author, and carried out full medical approval on all materials to ensure compliance with regulations. The sponsorship fee included an honorarium for the author. ...

Content for healthcare professionals

Access to this content is restricted to UK-based doctors, nurses, and pharmacists

If you are a UK-based doctor, nurse, or pharmacist, you must sign in to your account or register (for free) if you do not already have one. 

Return to homepage